Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...

Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...

On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...

Denali Therapeutics' innovative approach to neurological disorders and strong financial strategy position it as a leader in ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

Those with one copy are at increased risk too. Leqembi, which is developed by the Japanese pharmaceutical company Eisai and ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...